Thursday, 23 November 2017
Latest news
Main » Endo International PLC (ENDP) Releases Q3 Earnings Guidance

Endo International PLC (ENDP) Releases Q3 Earnings Guidance

15 November 2017

The last stock close price is up -26.00% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time.

Several research analysts have weighed in on the company. Comparatively, Endo International plc posted earnings of $1.09 per share in the same quarter past year. Cowen and Company reissued a hold rating and issued a $16.00 price target on shares of Endo International PLC in a research note on Thursday, August 10th. Its last month's stock price volatility remained 8.7% which for the week stands at 8.09%. Finally, Deutsche Bank AG dropped their target price on Endo International PLC from $18.00 to $15.00 and set a buy rating on the stock in a research report on Friday, July 7th. Marshall Wace LLP now owns 73,821 shares of the company's stock valued at $1,151,000 after buying an additional 65,744 shares during the period. The stock presently has an average rating of Hold and a consensus target price of $11.67.

Endo International plc (ENDP) added 13.79% to reach $6.93 in the previous trading session. 12,136,900 shares of the company's stock were exchanged, compared to its average volume of 7,342,927.

More news: World's 'most beautiful' diamond sold at auction for £25.5m

Having a look in a broader way analysts from brokerage firms on the street with an extensive view have high price target of Endo Int'l Plc (NASDAQ:ENDP) at $17 and with a conformist view have low price target of $5.2 while the stock's latest closing price was $6.69. The stock is now moving below its 20-Day Simple Moving Average of -1.34% with a 50-Day Simple Moving Average of -15.42 percent.

However looking at valuation ratios the stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last posted its earnings results on Thursday, November 9th.

More news: Election Commission bars BJP from using the term 'Pappu' in Gujarat elections

Maximum and minimum EPS estimate for the current quarter is projected at $0.78 and $0.55, respectively, according to 19 analysts. Endo International PLC had a positive return on equity of 66.98% and a negative net margin of 126.97%. During the same period last year, the firm earned $1.01 EPS. analysts predict that Endo International PLC will post 3.54 earnings per share for the current fiscal year.

Shares of Endo International PLC (NASDAQ:ENDP) opened at 14.63 on Friday. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & worldwide trademark & copyright law. The correct version of this report can be read at https://www.dispatchtribunal.com/2017/11/13/endo-international-plc-endp-pt-lowered-to-7-00.html. Oppenheimer Holdings, Inc. restated a hold rating on shares of Endo International PLC in a research report on Tuesday, August 8th. Ameriprise Financial Inc. now owns 581,552 shares of the company's stock worth $6,497,000 after acquiring an additional 27,414 shares during the period. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

A number of institutional investors have recently bought and sold shares of the stock. Finally, Canada Pension Plan Investment Board boosted its holdings in shares of Endo International PLC by 93.4% during the second quarter. Alps Advisors Inc. raised its holdings in shares of Endo International PLC by 9.3% in the third quarter.

More news: Manchester United can Sign €80m Star for €45m in January - Mou's Priority

Newell Brands Inc. (NWL) shares declined -2.66% and ended the day at $29.3. Hedge funds and other institutional investors own 96.61% of the company's stock. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, including attention deficit hyperactivity disorder, pain, womenÂ's health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, as well as for government healthcare programs. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel for pain, urology, endocrinology, and oncology.

Endo International PLC (ENDP) Releases Q3 Earnings Guidance